These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The DDAH-ADMA-NOS pathway. Leiper JM Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814 [TBL] [Abstract][Full Text] [Related]
3. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Feng M; Liu L; Guo Z; Xiong Y Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305 [TBL] [Abstract][Full Text] [Related]
4. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Achan V; Tran CT; Arrigoni F; Whitley GS; Leiper JM; Vallance P Circ Res; 2002 Apr; 90(7):764-9. PubMed ID: 11964368 [TBL] [Abstract][Full Text] [Related]
5. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Palm F; Onozato ML; Luo Z; Wilcox CS Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965 [TBL] [Abstract][Full Text] [Related]
6. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine. Yin QF; Fu SH; He P; Xiong Y Atherosclerosis; 2007 Jan; 190(1):53-61. PubMed ID: 16533509 [TBL] [Abstract][Full Text] [Related]
7. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Ueda S; Kato S; Matsuoka H; Kimoto M; Okuda S; Morimatsu M; Imaizumi T Circ Res; 2003 Feb; 92(2):226-33. PubMed ID: 12574151 [TBL] [Abstract][Full Text] [Related]
8. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Tan B; Jiang DJ; Huang H; Jia SJ; Jiang JL; Hu CP; Li YJ Vascul Pharmacol; 2007 May; 46(5):338-45. PubMed ID: 17293168 [TBL] [Abstract][Full Text] [Related]
12. The biology and therapeutic potential of the DDAH/ADMA pathway. Arrigoni F; Ahmetaj B; Leiper J Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398 [TBL] [Abstract][Full Text] [Related]
13. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239 [TBL] [Abstract][Full Text] [Related]
14. Endogenous inhibitors of nitric oxide and preeclampsia: a review. Slaghekke F; Dekker G; Jeffries B J Matern Fetal Neonatal Med; 2006 Aug; 19(8):447-52. PubMed ID: 16966108 [TBL] [Abstract][Full Text] [Related]
19. The DDAH/ADMA pathway in the control of endothelial cell migration and angiogenesis. Fiedler LR; Wojciak-Stothard B Biochem Soc Trans; 2009 Dec; 37(Pt 6):1243-7. PubMed ID: 19909255 [TBL] [Abstract][Full Text] [Related]
20. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Tojo A; Welch WJ; Bremer V; Kimoto M; Kimura K; Omata M; Ogawa T; Vallance P; Wilcox CS Kidney Int; 1997 Dec; 52(6):1593-601. PubMed ID: 9407505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]